

# Cristina R Antonescu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7045571/publications.pdf>

Version: 2024-02-01

326  
papers

34,532  
citations

2427

97  
h-index

4117

175  
g-index

332  
all docs

332  
docs citations

332  
times ranked

21783  
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>RREB1::MRTFB</i> fusion-positive extra-glossal mesenchymal neoplasms: A series of five cases expanding their anatomic distribution and highlighting significant morphological and phenotypic diversity. <i>Genes Chromosomes and Cancer</i> , 2023, 62, 5-16.	2.8	8
2	Uterine PEComas: correlation between melanocytic marker expression and TSC alterations/TFE3 fusions. <i>Modern Pathology</i> , 2022, 35, 515-523.	5.5	19
3	Low-grade endometrial stromal sarcoma-like tumors in male with <i>JAZF1</i> gene fusions. <i>Genes Chromosomes and Cancer</i> , 2022, 61, 63-70.	2.8	2
4	Neuregulin 1 ( <i>NRG1</i> ) fusion-positive high-grade spindle cell sarcoma: A distinct group of soft tissue tumors with metastatic potential. <i>Genes Chromosomes and Cancer</i> , 2022, 61, 123-130.	2.8	7
5	Clinicopathologic and survival correlates of embryonal rhabdomyosarcoma driven by <i>RAS</i> / <i>RAF</i> mutations. <i>Genes Chromosomes and Cancer</i> , 2022, 61, 131-137.	2.8	8
6	Whole Exome Sequencing Identifies Somatic Variants in an Oral Composite Hemangioendothelioma Characterized by YAP1-MAML2 Fusion. <i>Head and Neck Pathology</i> , 2022, 16, 849-856.	2.6	6
7	Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal Tumor. <i>Journal of Clinical Oncology</i> , 2022, 40, 997-1008.	1.6	13
8	A Phase Ib/II Randomized Study of RO4929097, a Gamma-Secretase or Notch Inhibitor with or without Vismodegib, a Hedgehog Inhibitor, in Advanced Sarcoma. <i>Clinical Cancer Research</i> , 2022, 28, 1586-1594.	7.0	20
9	Phase Ib Trial of the Combination of Imatinib and Binimetinib in Patients with Advanced Gastrointestinal Stromal Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 1507-1517.	7.0	3
10	The genetics of vascular tumours: an update. <i>Histopathology</i> , 2022, 80, 19-32.	2.9	10
11	<i>FGFR2::TACC2</i> fusion as a novel <i>KIT</i> -independent mechanism of targeted therapy failure in a multidrug-resistant gastrointestinal stromal tumor. <i>Genes Chromosomes and Cancer</i> , 2022, 61, 412-419.	2.8	4
12	Primary Mesenchymal Tumors of the Thyroid Gland: A Modern Retrospective Cohort Including the First Case of TFE3-Translocated Malignant Perivascular Epithelioid Cell Tumor (PEComa). <i>Head and Neck Pathology</i> , 2022, , 1.	2.6	6
13	Expanding the spectrum of mesenchymal neoplasms with <i>NR1D1</i> -rearrangement. <i>Genes Chromosomes and Cancer</i> , 2022, 61, 420-426.	2.8	3
14	Comprehensive genomic profiling of EWSR1/FUS::CREB translocation-associated tumors uncovers prognostically significant recurrent genetic alterations and methylation-transcriptional correlates. <i>Modern Pathology</i> , 2022, 35, 1055-1065.	5.5	13
15	Teratocarcinosarcoma-Like and Adamantinoma-Like Head and Neck Neoplasms Harboring NAB2::STAT6: Unusual Variants of Solitary Fibrous Tumor or Novel Tumor Entities?. <i>Head and Neck Pathology</i> , 2022, 16, 746-754.	2.6	9
16	PEComa-like Neoplasms Characterized by ASPSCR1-TFE3 Fusion. <i>American Journal of Surgical Pathology</i> , 2022, 46, 1153-1159.	3.7	6
17	Clinical, genomic, and transcriptomic correlates of response to immune checkpoint blockade-based therapy in a cohort of patients with angiosarcoma treated at a single center. , 2022, 10, e004149.		20
18	Recurrent <i>PTBP1::MAML2</i> fusions in composite hemangioendothelioma with neuroendocrine differentiation: A report of two cases involving neck lymph nodes. <i>Genes Chromosomes and Cancer</i> , 2022, 61, 187-193.	2.8	11

#	ARTICLE	IF	CITATIONS
19	A novel <i>WWTR1::AFF2</i> fusion in an intra-abdominal soft tissue sarcoma with associated endometriosis. <i>Genes Chromosomes and Cancer</i> , 2022, 61, 497-502.	2.8	2
20	<i>NUTM1</i> fusion positive malignant neoplasms of the genitourinary tract: A report of six cases highlighting involvement of unusual anatomic locations and histologic heterogeneity. <i>Genes Chromosomes and Cancer</i> , 2022, 61, 542-550.	2.8	5
21	Ewing sarcoma and related <i>FET</i> family translocation-associated round cell tumors: A century of clinical and scientific progress. <i>Genes Chromosomes and Cancer</i> , 2022, 61, 509-517.	2.8	5
22	Primary renal sarcoma with <i>SS18::POU5F1</i> gene fusion. <i>Genes Chromosomes and Cancer</i> , 2022, 61, 572-577.	2.8	3
23	<i>ZFP64::NCOA3</i> gene fusion defines a novel subset of spindle cell rhabdomyosarcoma. <i>Genes Chromosomes and Cancer</i> , 2022, 61, 645-652.	2.8	5
24	Recurrent <i>KAT6B/A::KANSL1</i> Fusions Characterize a Potentially Aggressive Uterine Sarcoma Morphologically Overlapping With Low-grade Endometrial Stromal Sarcoma. <i>American Journal of Surgical Pathology</i> , 2022, 46, 1298-1308.	3.7	4
25	<i>EWSR1::YY1</i> fusion positive peritoneal epithelioid mesothelioma harbors mesothelioma epigenetic signature: Report of 3 cases in support of an emerging entity. <i>Genes Chromosomes and Cancer</i> , 2022, 61, 592-602.	2.8	7
26	Mesenchymal chondrosarcoma of the head and neck with <i>HEY1::NCOA2</i> fusion: A clinicopathologic and molecular study of 13 cases with emphasis on diagnostic pitfalls. <i>Genes Chromosomes and Cancer</i> , 2022, 61, 670-677.	2.8	6
27	Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets. <i>Nature Communications</i> , 2022, 13, .	12.8	63
28	Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma. <i>Nature Communications</i> , 2022, 13, .	12.8	21
29	Myxoid pleomorphic liposarcoma is distinguished from other liposarcomas by widespread loss of heterozygosity and significantly worse overall survival: a genomic and clinicopathologic study. <i>Modern Pathology</i> , 2022, 35, 1644-1655.	5.5	12
30	Recurrent <i>VGLL3</i> fusions define a distinctive subset of spindle cell rhabdomyosarcoma with an indolent clinical course and striking predilection for the head and neck. <i>Genes Chromosomes and Cancer</i> , 2022, 61, 701-709.	2.8	14
31	PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry. <i>Cancer Discovery</i> , 2022, 12, 2120-2139.	9.4	14
32	DICER1-Associated Anaplastic Sarcoma of the Kidney With Coexisting Activating PDGFRA D842V Mutations and Response to Targeted Kinase Inhibitors in One Patient. <i>JCO Precision Oncology</i> , 2022, .	3.0	1
33	Prognostic Factors After Neoadjuvant Imatinib for Newly Diagnosed Primary Gastrointestinal Stromal Tumor. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 1828-1836.	1.7	10
34	Targeted RNA expression profiling identifies high-grade endometrial stromal sarcoma as a clinically relevant molecular subtype of uterine sarcoma. <i>Modern Pathology</i> , 2021, 34, 1008-1016.	5.5	27
35	Epithelioid hemangioma of bone harboring <i>FOS</i> and <i>FOSB</i> gene rearrangements: A clinicopathologic and molecular study. <i>Genes Chromosomes and Cancer</i> , 2021, 60, 17-25.	2.8	28
36	Novel <i>GATA6-FOXO1</i> fusions in a subset of epithelioid hemangioma. <i>Modern Pathology</i> , 2021, 34, 934-941.	5.5	27

#	ARTICLE	IF	CITATIONS
37	Pediatric fibromyxoid soft tissue tumor with <scp><i>PLAG1</i></scp> fusion: A novel entity?. Genes Chromosomes and Cancer, 2021, 60, 263-271.	2.8	16
38	A novel low-grade nasopharyngeal adenocarcinoma characterized by a <i>GOLGB1</i><BRAF</i> fusion gene. Genes Chromosomes and Cancer, 2021, 60, 49-53.	2.8	3
39	Outcome of 1000 Patients With Gastrointestinal Stromal Tumor (GIST) Treated by Surgery in the Pre- and Post-imatinib Eras. Annals of Surgery, 2021, 273, 128-138.	4.2	62
40	A Poorly Differentiated Non-keratinizing Sinonasal Squamous Cell Carcinoma with a Novel ETV6-TNFRSF8 Fusion Gene. Head and Neck Pathology, 2021, 15, 1284-1288.	2.6	7
41	Pediatric Mesothelioma With ALK Fusions. American Journal of Surgical Pathology, 2021, 45, 653-661.	3.7	22
42	Recurrent MEIS1-NCOA2/1 fusions in a subset of low-grade spindle cell sarcomas frequently involving the genitourinary and gynecologic tracts. Modern Pathology, 2021, 34, 1203-1212.	5.5	27
43	Hyalinizing epithelioid tumors with <scp><i>OGT</i><FOXO</i></scp> fusions. A case report of a non-accral soft tissue mass harboring a novel <scp><i>FOXO4</i></scp> gene rearrangement. Genes Chromosomes and Cancer, 2021, 60, 498-503.	2.8	7
44	Hybrid schwannoma-perineurioma frequently harbors VGLL3 rearrangement. Modern Pathology, 2021, 34, 1116-1124.	5.5	17
45	<scp><i>RREB1</i><MKL2</i></scp> fusion in a spindle cell sinonasal sarcoma: biphenotypic sinonasal sarcoma or ectomesenchymal chondromyxoid tumor in an unusual site?. Genes Chromosomes and Cancer, 2021, 60, 565-570.	2.8	10
46	Unclassified low grade spindle cell sarcoma with storiform pattern characterized by recurrent novel EWSR1/FUS-NACC1 fusions. Modern Pathology, 2021, 34, 1541-1546.	5.5	5
47	Anti-IL17 antibody Secukinumab therapy is associated with ossification in giant cell tumor of bone: a case report of pathologic similarities and therapeutic potential similar to Denosumab. BMC Musculoskeletal Disorders, 2021, 22, 320.	1.9	3
48	Recurrent YAP1-TFE3 Gene Fusions in Clear Cell Stromal Tumor of the Lung. American Journal of Surgical Pathology, 2021, 45, 1541-1549.	3.7	16
49	Sarcomas with sclerotic epithelioid phenotype harboring novel <scp><i>EWSR1</i><SSX1</i></scp> fusions. Genes Chromosomes and Cancer, 2021, 60, 616-622.	2.8	9
50	Head and neck rhabdomyosarcoma with <i>TFCP2</i> fusions and ALK overexpression: a clinicopathological and molecular analysis of 11 cases. Histopathology, 2021, 79, 347-357.	2.9	53
51	A Novel NIPBL-NACC1 Gene Fusion Is Characteristic of the Cholangioblastic Variant of Intrahepatic Cholangiocarcinoma. American Journal of Surgical Pathology, 2021, 45, 1550-1560.	3.7	23
52	Generation of human embryonic stem cell models to exploit the EWSR1-CREB fusion promiscuity as a common pathway of transformation in human tumors. Oncogene, 2021, 40, 5095-5104.	5.9	7
53	Targeted <scp>RNA</scp> sequencing in the routine clinical detection of fusion genes in salivary gland tumors. Genes Chromosomes and Cancer, 2021, 60, 695-708.	2.8	11
54	<scp>PLAG1</scp> rearrangement in a uterine leiomyosarcoma with myxoid stroma and heterologous differentiation. Genes Chromosomes and Cancer, 2021, 60, 713-717.	2.8	13

#	ARTICLE	IF	CITATIONS
55	Intimal sarcomas and undifferentiated cardiac sarcomas carry mutually exclusive MDM2, MDM4, and CDK6 amplifications and share a common DNA methylation signature. <i>Modern Pathology</i> , 2021, 34, 2122-2129.	5.5	17
56	Gastrointestinal stromal tumors with <i>BRAF</i> gene fusions. A report of two cases showing low or absent <i>KIT</i> expression resulting in diagnostic pitfalls. <i>Genes Chromosomes and Cancer</i> , 2021, 60, 789-795.	2.8	11
57	A unique epithelioid vascular neoplasm of bone characterized by <i>EWSR1</i> / <i>FUS</i> fusions. <i>Genes Chromosomes and Cancer</i> , 2021, 60, 762-771.	2.8	11
58	The impact of MYC gene amplification on the clinicopathological features and prognosis of radiation-associated angiosarcomas of the breast. <i>Histopathology</i> , 2021, 79, 836-846.	2.9	9
59	Sarcoma classification by DNA methylation profiling. <i>Nature Communications</i> , 2021, 12, 498.	12.8	237
60	Case Report: Response to Regional Melphalan via Limb Infusion and Systemic PD1 Blockade in Recurrent Myxofibrosarcoma: A Report of 2 Cases. <i>Frontiers in Oncology</i> , 2021, 11, 725484.	2.8	4
61	HUGO Gene Nomenclature Committee (HGNC) recommendations for the designation of gene fusions. <i>Leukemia</i> , 2021, 35, 3040-3043.	7.2	42
62	Advances in the molecular characterization of mesenchymal neoplasms of the gynecologic tract. <i>Genes Chromosomes and Cancer</i> , 2021, 60, 127-128.	2.8	0
63	Prognostic stratification of clinical and molecular epithelioid hemangioendothelioma subsets. <i>Modern Pathology</i> , 2020, 33, 591-602.	5.5	87
64	Message from the new Editor-in-Chief. <i>Genes Chromosomes and Cancer</i> , 2020, 59, 5-5.	2.8	0
65	A molecular study of synovial chondromatosis. <i>Genes Chromosomes and Cancer</i> , 2020, 59, 144-151.	2.8	31
66	A novel <i>RBMX</i> / <i>TFE3</i> gene fusion in a highly aggressive pediatric renal perivascular epithelioid cell tumor. <i>Genes Chromosomes and Cancer</i> , 2020, 59, 58-63.	2.8	25
67	Genetic diversity in alveolar soft part sarcoma: A subset contain variant fusion genes, highlighting broader molecular kinship with other MiT family tumors. <i>Genes Chromosomes and Cancer</i> , 2020, 59, 23-29.	2.8	19
68	Pan-Trk immunohistochemistry is a sensitive and specific ancillary tool for diagnosing secretory carcinoma of the salivary gland and detecting <i>ETV6</i> / <i>NTRK3</i> fusion. <i>Histopathology</i> , 2020, 76, 375-382.	2.9	57
69	Clinical and molecular characterization of primary sclerosing epithelioid fibrosarcoma of bone and review of the literature. <i>Genes Chromosomes and Cancer</i> , 2020, 59, 217-224.	2.8	26
70	Novel <i>SS18</i> / <i>NEDD4</i> gene fusion in a primary renal synovial sarcoma. <i>Genes Chromosomes and Cancer</i> , 2020, 59, 203-208.	2.8	16
71	Recurrent YAP1 and KMT2A Gene Rearrangements in a Subset of MUC4-negative Sclerosing Epithelioid Fibrosarcoma. <i>American Journal of Surgical Pathology</i> , 2020, 44, 368-377.	3.7	61
72	Novel SRF-ICA1L Fusions in Cellular Myoid Neoplasms With Potential For Malignant Behavior. <i>American Journal of Surgical Pathology</i> , 2020, 44, 55-60.	3.7	15

#	ARTICLE	IF	CITATIONS
73	Uterine Tumor Resembling Ovarian Sex Cord Tumor (UTROSCT). American Journal of Surgical Pathology, 2020, 44, 30-42.	3.7	56
74	Ewing sarcoma with <i>FEV</i> gene rearrangements is a rare subset with predilection for extraskeletal locations and aggressive behavior. Genes Chromosomes and Cancer, 2020, 59, 286-294.	2.8	18
75	Expanding the differential of superficial tumors with round cell morphology: Report of three cases of CIC rearranged sarcoma, a potentially underrecognized entity. Journal of Cutaneous Pathology, 2020, 47, 535-540.	1.3	8
76	Genetic basis of SMARCB1 protein loss in 22 sinonasal carcinomas. Human Pathology, 2020, 104, 105-116.	2.0	14
77	A Molecular Reappraisal of Glomus Tumors and Related Pericytic Neoplasms With Emphasis on NOTCH-gene Fusions. American Journal of Surgical Pathology, 2020, 44, 1556-1562.	3.7	30
78	The V654A second-site KIT mutation increases tumor oncogenesis and STAT activation in a mouse model of gastrointestinal stromal tumor. Oncogene, 2020, 39, 7153-7165.	5.9	8
79	Biphasic Hyalinizing Psammomatous Renal Cell Carcinoma (BHP RCC). American Journal of Surgical Pathology, 2020, 44, 901-916.	3.7	34
80	EWSR1/FUS-CREB fusions define a distinctive malignant epithelioid neoplasm with predilection for mesothelial-lined cavities. Modern Pathology, 2020, 33, 2233-2243.	5.5	49
81	HLA Genotyping in Synovial Sarcoma: Identifying HLA-A*02 and Its Association with Clinical Outcome. Clinical Cancer Research, 2020, 26, 5448-5455.	7.0	12
82	Clinical Outcome of Leiomyosarcomas With Somatic Alteration in Homologous Recombination Pathway Genes. JCO Precision Oncology, 2020, 4, 1350-1360.	3.0	18
83	The clinical heterogeneity of round cell sarcomas with <i>EWSR1</i> / <i>FUS</i> gene fusions: Impact of gene fusion type on clinical features and outcome. Genes Chromosomes and Cancer, 2020, 59, 525-534.	2.8	35
84	High-grade transformation of low-grade endometrial stromal sarcomas lacking YWHAE and BCOR genetic abnormalities. Modern Pathology, 2020, 33, 1861-1870.	5.5	26
85	Undifferentiated round cell sarcoma with BCOR internal tandem duplications (ITD) or YWHAE fusions: a clinicopathologic and molecular study. Modern Pathology, 2020, 33, 1669-1677.	5.5	29
86	BCOR Expression in Mullerian Adenosarcoma. American Journal of Surgical Pathology, 2020, 44, 765-770.	3.7	21
87	Soft tissue tumors characterized by a wide spectrum of kinase fusions share a lipofibromatosis-like neural tumor pattern. Genes Chromosomes and Cancer, 2020, 59, 575-583.	2.8	56
88	Undifferentiated round cell sarcomas with novel SS18-POU5F1 fusions. Genes Chromosomes and Cancer, 2020, 59, 620-626.	2.8	15
89	Emerging soft tissue tumors with kinase fusions: An overview of the recent literature with an emphasis on diagnostic criteria. Genes Chromosomes and Cancer, 2020, 59, 437-444.	2.8	69
90	Variant <i>WWTR1</i> gene fusions in epithelioid hemangioendothelioma: A genetic subset associated with cardiac involvement. Genes Chromosomes and Cancer, 2020, 59, 389-395.	2.8	35

#	ARTICLE	IF	CITATIONS
91	A morphologic and molecular reappraisal of myoepithelial tumors of soft tissue, bone, and viscera with EWSR1 and FUS gene rearrangements. <i>Genes Chromosomes and Cancer</i> , 2020, 59, 348-356.	2.8	44
92	NTRK3 overexpression in undifferentiated sarcomas with YWHAE and BCOR genetic alterations. <i>Modern Pathology</i> , 2020, 33, 1341-1349.	5.5	53
93	Cutaneous intravascular epithelioid hemangioma. A clinicopathological and molecular study of 21 cases. <i>Modern Pathology</i> , 2020, 33, 1527-1536.	5.5	11
94	Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab. <i>JAMA Oncology</i> , 2020, 6, 402.	7.1	125
95	Head and Neck Mesenchymal Neoplasms With GLI1 Gene Alterations. <i>American Journal of Surgical Pathology</i> , 2020, 44, 729-737.	3.7	46
96	NKX3-1 Is a Useful Immunohistochemical Marker of EWSR1-NFATC2 Sarcoma and Mesenchymal Chondrosarcoma. <i>American Journal of Surgical Pathology</i> , 2020, 44, 719-728.	3.7	54
97	Recurrent YAP1 and MAML2 Gene Rearrangements in Retiform and Composite Hemangioendothelioma. <i>American Journal of Surgical Pathology</i> , 2020, 44, 1677-1684.	3.7	51
98	A phase II study of MEK162 (binimetinib [BINI]) in combination with imatinib in patients with untreated advanced gastrointestinal stromal tumor (GIST).. <i>Journal of Clinical Oncology</i> , 2020, 38, 11508-11508.	1.6	10
99	A multicenter phase II study of nivolumab +/- ipilimumab for patients with metastatic sarcoma (Alliance) Tj ETQq1 1,0784314 rgBT /O	1.6	28
100	HLA genotyping in synovial sarcoma: Identifying HLA-A*02 and its association with clinical outcome.. <i>Journal of Clinical Oncology</i> , 2020, 38, e23560-e23560.	1.6	0
101	A phase Ib study of BCJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumor. <i>Investigational New Drugs</i> , 2019, 37, 282-290.	2.6	32
102	Expanding the Molecular Characterization of Thoracic Inflammatory Myofibroblastic Tumors beyond ALK Gene Rearrangements. <i>Journal of Thoracic Oncology</i> , 2019, 14, 825-834.	1.1	62
103	GLI1-amplifications expand the spectrum of soft tissue neoplasms defined by GLI1 gene fusions. <i>Modern Pathology</i> , 2019, 32, 1617-1626.	5.5	70
104	The histologic spectrum of soft tissue spindle cell tumors with <i>NTRK3</i> gene rearrangements. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 739-746.	2.8	86
105	EWSR1/FUS-NFATc2 rearranged round cell sarcoma: clinicopathological series of 4 cases and literature review. <i>Human Pathology</i> , 2019, 90, 45-53.	2.0	63
106	<i>PRRX1</i> rearrangement characterizes a distinctive fibroblastic neoplasm. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 705-712.	2.8	23
107	JAK2/PD-L1/PD-L2 (9p24.1) amplifications in renal cell carcinomas with sarcomatoid transformation: implications for clinical management. <i>Modern Pathology</i> , 2019, 32, 1344-1358.	5.5	49
108	DNA methylation profiling distinguishes Ewing-like sarcoma with EWSR1-NFATc2 fusion from Ewing sarcoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1273-1281.	2.5	50



#	ARTICLE	IF	CITATIONS
109	Novel PLAG1 Gene Rearrangement Distinguishes a Subset of Uterine Myxoid Leiomyosarcoma From Other Uterine Myxoid Mesenchymal Tumors. American Journal of Surgical Pathology, 2019, 43, 382-388.	3.7	53
110	Novel recurrent PHF1&TFE3 fusions in ossifying fibromyxoid tumors. Genes Chromosomes and Cancer, 2019, 58, 643-649.	2.8	39
111	The repertoire of genetic alterations in salivary duct carcinoma including a novel HNRNPH3-ALK rearrangement. Human Pathology, 2019, 88, 66-77.	2.0	38
112	Uterine Tumor Resembling Ovarian Sex Cord Tumor. American Journal of Surgical Pathology, 2019, 43, 178-186.	3.7	72
113	Adamantinoma-like Ewing Sarcoma of the Salivary Glands. American Journal of Surgical Pathology, 2019, 43, 187-194.	3.7	53
114	Pericytoma With t(7;12) and ACTB-GLI1 Fusion. American Journal of Surgical Pathology, 2019, 43, 1682-1692.	3.7	45
115	Spindle Cell Tumors With RET Gene Fusions Exhibit a Morphologic Spectrum Akin to Tumors With NTRK Gene Fusions. American Journal of Surgical Pathology, 2019, 43, 1384-1391.	3.7	78
116	Clinicopathologic and Molecular Features of a Series of 41 Biphenotypic Sinonasal Sarcomas Expanding Their Molecular Spectrum. American Journal of Surgical Pathology, 2019, 43, 747-754.	3.7	65
117	Undifferentiated Uterine Sarcomas Represent Under-Recognized High-grade Endometrial Stromal Sarcomas. American Journal of Surgical Pathology, 2019, 43, 662-669.	3.7	61
118	Expanding the Spectrum of Intraosseous Rhabdomyosarcoma. American Journal of Surgical Pathology, 2019, 43, 695-702.	3.7	93
119	BCOR Overexpression in Renal Malignant Solitary Fibrous Tumors. American Journal of Surgical Pathology, 2019, 43, 773-782.	3.7	24
120	New advances in the molecular classification of pediatric mesenchymal tumors. Genes Chromosomes and Cancer, 2019, 58, 100-110.	2.8	22
121	Plexiform fibrohistiocytic tumor: imaging features and clinical findings. Skeletal Radiology, 2019, 48, 437-443.	2.0	12
122	MYOD1-mutant spindle cell and sclerosing rhabdomyosarcoma: an aggressive subtype irrespective of age. A reappraisal for molecular classification and risk stratification. Modern Pathology, 2019, 32, 27-36.	5.5	126
123	Preface. Genes Chromosomes and Cancer, 2019, 58, 73-74.	2.8	0
124	Genomic and transcriptomic characterisation of undifferentiated pleomorphic sarcoma of bone. Journal of Pathology, 2019, 247, 166-176.	4.5	28
125	Phase 2 study of the CDK4 inhibitor abemaciclib in dedifferentiated liposarcoma.. Journal of Clinical Oncology, 2019, 37, 11004-11004.	1.6	44
126	A phase II study of epacadostat and pembrolizumab in patients with advanced sarcoma.. Journal of Clinical Oncology, 2019, 37, 11049-11049.	1.6	12



#	ARTICLE	IF	CITATIONS
127	Sequenced circulating tumor (ct) DNA to detect the molecular landscape in advanced GIST.. Journal of Clinical Oncology, 2019, 37, 11036-11036.	1.6	0
128	Macrophages and CD8+ T Cells Mediate the Antitumor Efficacy of Combined CD40 Ligation and Imatinib Therapy in Gastrointestinal Stromal Tumors. Cancer Immunology Research, 2018, 6, 434-447.	3.4	49
129	NUTM1 Gene Fusions Characterize a Subset of Undifferentiated Soft Tissue and Visceral Tumors. American Journal of Surgical Pathology, 2018, 42, 636-645.	3.7	97
130	Mitochondrial Inhibition Augments the Efficacy of Imatinib by Resetting the Metabolic Phenotype of Gastrointestinal Stromal Tumor. Clinical Cancer Research, 2018, 24, 972-984.	7.0	42
131	Novel EWSR1-SMAD3 Gene Fusions in a Group of Acral Fibroblastic Spindle Cell Neoplasms. American Journal of Surgical Pathology, 2018, 42, 522-528.	3.7	57
132	A Distinct Malignant Epithelioid Neoplasm With GLI1 Gene Rearrangements, Frequent S100 Protein Expression, and Metastatic Potential. American Journal of Surgical Pathology, 2018, 42, 553-560.	3.7	109
133	NTRK Fusions Define a Novel Uterine Sarcoma Subtype With Features of Fibrosarcoma. American Journal of Surgical Pathology, 2018, 42, 791-798.	3.7	182
134	Array-based DNA-methylation profiling in sarcomas with small blue round cell histology provides valuable diagnostic information. Modern Pathology, 2018, 31, 1246-1256.	5.5	76
135	Lipofibromatosis-like neural tumor: Case report of a unique infantile presentation. JAAD Case Reports, 2018, 4, 185-188.	0.8	22
136	Genetic analyses of undifferentiated small round cell sarcoma identifies a novel sarcoma subtype with a recurrent <i>CRTC1-SS18</i> gene fusion. Journal of Pathology, 2018, 245, 186-196.	4.5	26
137	Cytoreductive Surgery for Metastatic Gastrointestinal Stromal Tumors Treated With Tyrosine Kinase Inhibitors. Annals of Surgery, 2018, 268, 296-302.	4.2	58
138	Recurrent BRAF Gene Fusions in a Subset of Pediatric Spindle Cell Sarcomas. American Journal of Surgical Pathology, 2018, 42, 28-38.	3.7	85
139	FOXF1 Defines the Core-Regulatory Circuitry in Gastrointestinal Stromal Tumor. Cancer Discovery, 2018, 8, 234-251.	9.4	49
140	ZC3H7B-BCOR high-grade endometrial stromal sarcomas: a report of 17 cases of a newly defined entity. Modern Pathology, 2018, 31, 674-684.	5.5	130
141	Recurrent RET Gene Rearrangements in Intraductal Carcinomas of Salivary Gland. American Journal of Surgical Pathology, 2018, 42, 442-452.	3.7	91
142	High sensitivity of FISH analysis in detecting homozygous <i>SMARCB1</i> deletions in poorly differentiated chordoma: a clinicopathologic and molecular study of nine cases. Genes Chromosomes and Cancer, 2018, 57, 89-95.	2.8	29
143	BCOR-CCNB3 Fusion Positive Sarcomas. American Journal of Surgical Pathology, 2018, 42, 604-615.	3.7	207
144	A Clinicopathologic Study of Head and Neck Malignant Peripheral Nerve Sheath Tumors. Head and Neck Pathology, 2018, 12, 151-159.	2.6	23

#	ARTICLE	IF	CITATIONS
145	PLAG1 immunohistochemistry is a sensitive marker for pleomorphic adenoma: a comparative study with <i>PLAG1</i> genetic abnormalities. <i>Histopathology</i> , 2018, 72, 285-293.	2.9	71
146	Expanding the Spectrum of Genetic Alterations in Pseudomyogenic Hemangioendothelioma With Recurrent Novel ACTB-FOSB Gene Fusions. <i>American Journal of Surgical Pathology</i> , 2018, 42, 1653-1661.	3.7	75
147	Novel MEIS1-NCOA2 Gene Fusions Define a Distinct Primitive Spindle Cell Sarcoma of the Kidney. <i>American Journal of Surgical Pathology</i> , 2018, 42, 1562-1570.	3.7	35
148	Uterine PEComas. <i>American Journal of Surgical Pathology</i> , 2018, 42, 1370-1383.	3.7	114
149	COP1/DET1/ETS axis regulates ERK transcriptome and sensitivity to MAPK inhibitors. <i>Journal of Clinical Investigation</i> , 2018, 128, 1442-1457.	8.2	30
150	A recurrent novel <i>MGA&NUTM1</i> fusion identifies a new subtype of high-grade spindle cell sarcoma. <i>Journal of Physical Education and Sports Management</i> , 2018, 4, a003194.	1.2	32
151	A novel group of spindle cell tumors defined by S100 and CD34 co&expression shows recurrent fusions involving RAF1, BRAF, and NTRK1/2 genes. <i>Genes Chromosomes and Cancer</i> , 2018, 57, 611-621.	2.8	144
152	Ectomesenchymal Chondromyxoid Tumor. <i>American Journal of Surgical Pathology</i> , 2018, 42, 1297-1305.	3.7	60
153	PDLIM7 and CDH18 regulate the turnover of MDM2 during CDK4/6 inhibitor therapy-induced senescence. <i>Oncogene</i> , 2018, 37, 5066-5078.	5.9	38
154	Type A thymoma presenting with bone metastasis. <i>Histopathology</i> , 2018, 73, 701-703.	2.9	1
155	Recurrent rearrangements of FOS and FOSB define osteblastoma. <i>Nature Communications</i> , 2018, 9, 2150.	12.8	106
156	Diffuse Strong BCOR Immunoreactivity Is a Sensitive and Specific Marker for Clear Cell Sarcoma of the Kidney (CCSK) in Pediatric Renal Neoplasia. <i>American Journal of Surgical Pathology</i> , 2018, 42, 1128-1131.	3.7	30
157	Dermatofibrosarcoma protuberans with a novel <i>COL6A3&PDGFD</i> fusion gene and apparent predilection for breast. <i>Genes Chromosomes and Cancer</i> , 2018, 57, 437-445.	2.8	61
158	A phase II study of talimogene laherparepvec (T-VEC) and pembrolizumab in patients with metastatic sarcoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 11516-11516.	1.6	6
159	A clinicopathologic study on SS18 fusion positive head and neck synovial sarcomas. <i>Oral Oncology</i> , 2017, 66, 46-51.	1.5	18
160	MAX inactivation is an early event in GIST development that regulates p16 and cell proliferation. <i>Nature Communications</i> , 2017, 8, 14674.	12.8	53
161	ETV transcriptional upregulation is more reliable than RNA sequencing algorithms and FISH in diagnosing round cell sarcomas with <i>CIC</i> gene rearrangements. <i>Genes Chromosomes and Cancer</i> , 2017, 56, 501-510.	2.8	52
162	<i>CIC-DUX4</i> Induces Small Round Cell Sarcomas Distinct from Ewing Sarcoma. <i>Cancer Research</i> , 2017, 77, 2927-2937.	0.9	85

#	ARTICLE	IF	CITATIONS
163	PCBD5 promotes site-specific oncogenic mutations in human tumors. <i>Nature Genetics</i> , 2017, 49, 1005-1014.	21.4	69
164	EWSR1 Fusions With CREB Family Transcription Factors Define a Novel Myxoid Mesenchymal Tumor With Predilection for Intracranial Location. <i>American Journal of Surgical Pathology</i> , 2017, 41, 482-490.	3.7	112
165	Primary Pulmonary Myxoid Sarcoma: A Newly Described Entity—Report of a Case and Review of the Literature. <i>International Journal of Surgical Pathology</i> , 2017, 25, 518-525.	0.8	18
166	BCOR upregulation in a poorly differentiated synovial sarcoma with <i>SS18L1</i> – <i>SSX1</i> fusion—A pathologic and molecular pitfall. <i>Genes Chromosomes and Cancer</i> , 2017, 56, 296-302.	2.8	30
167	Wnt/ $\beta$ -catenin Signaling Contributes to Tumor Malignancy and Is Targetable in Gastrointestinal Stromal Tumor. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1954-1966.	4.1	41
168	A Subset of Malignant Mesotheliomas in Young Adults Are Associated With Recurrent EWSR1/FUS-ATF1 Fusions. <i>American Journal of Surgical Pathology</i> , 2017, 41, 980-988.	3.7	77
169	Recurrent SRF-RELA Fusions Define a Novel Subset of Cellular Myofibroblast/Myopericytoma. <i>American Journal of Surgical Pathology</i> , 2017, 41, 677-684.	3.7	76
170	<i>TFG</i> – <i>MET</i> fusion in an infantile spindle cell sarcoma with neural features. <i>Genes Chromosomes and Cancer</i> , 2017, 56, 663-667.	2.8	57
171	RBM10-TFE3 Renal Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 2017, 41, 655-662.	3.7	92
172	BCOR is a robust diagnostic immunohistochemical marker of genetically diverse high-grade endometrial stromal sarcoma, including tumors exhibiting variant morphology. <i>Modern Pathology</i> , 2017, 30, 1251-1261.	5.5	112
173	ETV1-Positive Cells Give Rise to <i>BRAFV600E</i> -Mutant Gastrointestinal Stromal Tumors. <i>Cancer Research</i> , 2017, 77, 3758-3765.	0.9	12
174	Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1—a consensus overview. <i>Human Pathology</i> , 2017, 67, 1-10.	2.0	275
175	SMARCB1 (INI-1)-deficient Sinonasal Carcinoma. <i>American Journal of Surgical Pathology</i> , 2017, 41, 458-471.	3.7	198
176	Head and Neck Round Cell Sarcomas: A Comparative Clinicopathologic Analysis of 2 Molecular Subsets: Ewing and CIC-Rearranged Sarcomas. <i>Head and Neck Pathology</i> , 2017, 11, 450-459.	2.6	18
177	Sarcomas With CIC-rearrangements Are a Distinct Pathologic Entity With Aggressive Outcome. <i>American Journal of Surgical Pathology</i> , 2017, 41, 941-949.	3.7	278
178	Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab. <i>Clinical Cancer Research</i> , 2017, 23, 2972-2980.	7.0	106
179	Multi-dimensional genomic analysis of myoepithelial carcinoma identifies prevalent oncogenic gene fusions. <i>Nature Communications</i> , 2017, 8, 1197.	12.8	77
180	In-depth Genetic Analysis of Sclerosing Epithelioid Fibrosarcoma Reveals Recurrent Genomic Alterations and Potential Treatment Targets. <i>Clinical Cancer Research</i> , 2017, 23, 7426-7434.	7.0	73

#	ARTICLE	IF	CITATIONS
181	Rectal Gastrointestinal Stromal Tumor (GIST) in the Era of Imatinib: Organ Preservation and Improved Oncologic Outcome. <i>Annals of Surgical Oncology</i> , 2017, 24, 3972-3980.	1.5	59
182	Primary Renal Sarcomas With BCOR-CCNB3 Gene Fusion. <i>American Journal of Surgical Pathology</i> , 2017, 41, 1702-1712.	3.7	68
183	Direct engagement of the PI3K pathway by mutant KIT dominates oncogenic signaling in gastrointestinal stromal tumor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E8448-E8457.	7.1	34
184	Novel High-grade Endometrial Stromal Sarcoma. <i>American Journal of Surgical Pathology</i> , 2017, 41, 12-24.	3.7	115
185	Benign vascular lesions of the breast diagnosed by core needle biopsy do not require excision. <i>Histopathology</i> , 2017, 71, 795-804.	2.9	22
186	Recurrent BRAF Gene Rearrangements in Myxoinflammatory Fibroblastic Sarcomas, but Not Hemosiderotic Fibrolipomatous Tumors. <i>American Journal of Surgical Pathology</i> , 2017, 41, 1456-1465.	3.7	40
187	Primary cutaneous adenoid cystic carcinoma with <i>MYB</i> aberrations: report of three cases and comprehensive review of the literature. <i>Journal of Cutaneous Pathology</i> , 2017, 44, 201-209.	1.3	19
188	PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors. <i>Clinical Cancer Research</i> , 2017, 23, 454-465.	7.0	126
189	Expanding the molecular signature of ossifying fibromyxoid tumors with two novel gene fusions: <i>CREBBP</i> and <i>KDM2A</i> . <i>Genes Chromosomes and Cancer</i> , 2017, 56, 42-50.	2.8	51
190	A multi-center phase II study of nivolumab +/- ipilimumab for patients with metastatic sarcoma (Alliance A091401).. <i>Journal of Clinical Oncology</i> , 2017, 35, 11007-11007.	1.6	26
191	The clinical impact of performing routine next generation sequencing (NGS) in gastrointestinal stromal tumors (GIST).. <i>Journal of Clinical Oncology</i> , 2017, 35, 11010-11010.	1.6	3
192	A phase Ib study of BCG398 in combination with imatinib in patients with advanced gastrointestinal stromal tumor (GIST).. <i>Journal of Clinical Oncology</i> , 2017, 35, 11039-11039.	1.6	0
193	Novel PAX3-NCOA1 Fusions in Biphenotypic Sinonasal Sarcoma With Focal Rhabdomyoblastic Differentiation. <i>American Journal of Surgical Pathology</i> , 2016, 40, 51-59.	3.7	102
194	Recurrent <i>MALAT1-GLI1</i> oncogenic fusion and <i>GLI1</i> up-regulation define a subset of plexiform fibromyxoma. <i>Journal of Pathology</i> , 2016, 239, 335-343.	4.5	98
195	Recurrent CIC Gene Abnormalities in Angiosarcomas. <i>American Journal of Surgical Pathology</i> , 2016, 40, 645-655.	3.7	157
196	Novel BCOR-MAML3 and ZC3H7B-BCOR Gene Fusions in Undifferentiated Small Blue Round Cell Sarcomas. <i>American Journal of Surgical Pathology</i> , 2016, 40, 433-442.	3.7	145
197	TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers. <i>American Journal of Surgical Pathology</i> , 2016, 40, 723-737.	3.7	168
198	Targeted exome sequencing profiles genetic alterations in leiomyosarcoma. <i>Genes Chromosomes and Cancer</i> , 2016, 55, 124-130.	2.8	38

#	ARTICLE	IF	CITATIONS
199	Ewing sarcoma with <sc><i>ERG</i></sc> gene rearrangements: A molecular study focusing on the prevalence of <sc><i>FUS</i></sc> and common pitfalls in detecting <sc><i>EWSR1</i></sc> fusions by <sc>FISH</sc>. <i>Genes Chromosomes and Cancer</i> , 2016, 55, 340-349.	2.8	96
200	Secondary <i>EWSR1</i> gene abnormalities in <i>SMARCB1</i>-deficient tumors with 22q11.2 regional deletions: Potential pitfalls in interpreting <i>EWSR1</i> FISH results. <i>Genes Chromosomes and Cancer</i> , 2016, 55, 767-776.	2.8	44
201	Somatic <i>PIK3CA</i> mutations as a driver of sporadic venous malformations. <i>Science Translational Medicine</i> , 2016, 8, 332ra42.	12.4	147
202	Epithelioid Hemangioendothelioma: a Rare Primary Thyroid Tumor with Confirmation of WWTR1 and CAMTA1 Rearrangements. <i>Endocrine Pathology</i> , 2016, 27, 147-152.	9.0	8
203	Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With <i>CDK4</i> Inhibitor Palbociclib. <i>JAMA Oncology</i> , 2016, 2, 937.	7.1	241
204	Biphenotypic sinonasal sarcoma: an expanded immunoprofile including consistent nuclear $\beta$ -catenin positivity and absence of SOX10 expression. <i>Human Pathology</i> , 2016, 55, 44-50.	2.0	80
205	A clinicopathologic study of head and neck rhabdomyosarcomas showing FOXO1 fusion-positive alveolar and MYOD1 -mutant sclerosing are associated with unfavorable outcome. <i>Oral Oncology</i> , 2016, 61, 89-97.	1.5	32
206	Long-term effect of chemotherapy+intensity-modulated radiation therapy (chemo-IMRT) on dentofacial development in head and neck rhabdomyosarcoma patients. <i>Pediatric Hematology and Oncology</i> , 2016, 33, 383-392.	0.8	25
207	A Molecular Study of Pediatric Spindle and Sclerosing Rhabdomyosarcoma. <i>American Journal of Surgical Pathology</i> , 2016, 40, 224-235.	3.7	208
208	Recurrent NTRK1 Gene Fusions Define a Novel Subset of Locally Aggressive Lipofibromatosis-like Neural Tumors. <i>American Journal of Surgical Pathology</i> , 2016, 40, 1407-1416.	3.7	177
209	BCOR Overexpression Is a Highly Sensitive Marker in Round Cell Sarcomas With BCOR Genetic Abnormalities. <i>American Journal of Surgical Pathology</i> , 2016, 40, 1670-1678.	3.7	168
210	Gene fusions in soft tissue tumors: Recurrent and overlapping pathogenetic themes. <i>Genes Chromosomes and Cancer</i> , 2016, 55, 291-310.	2.8	107
211	Loss of H3K27me3 Expression Is a Highly Sensitive Marker for Sporadic and Radiation-induced MPNST. <i>American Journal of Surgical Pathology</i> , 2016, 40, 479-489.	3.7	224
212	Ga-68 DOTATOC PET/CT-Guided Biopsy and Cryoablation with Autoradiography of Biopsy Specimen for Treatment of Tumor-Induced Osteomalacia. <i>CardioVascular and Interventional Radiology</i> , 2016, 39, 1352-1357.	2.0	19
213	Clinical and molecular heterogeneity of head and neck spindle cell and sclerosing rhabdomyosarcoma. <i>Oral Oncology</i> , 2016, 58, e6-e11.	1.5	23
214	Recurrent BCOR Internal Tandem Duplication and YWHAE-NUTM2B Fusions in Soft Tissue Undifferentiated Round Cell Sarcoma of Infancy. <i>American Journal of Surgical Pathology</i> , 2016, 40, 1009-1020.	3.7	155
215	Frequent HRAS Mutations in Malignant Ectomesenchymoma. <i>American Journal of Surgical Pathology</i> , 2016, 40, 876-885.	3.7	24
216	Primary Ewing Family of Tumors of the Jaw Has a Better Prognosis Compared to Tumors of Extragenathic Sites. <i>Journal of Oral and Maxillofacial Surgery</i> , 2016, 74, 973-981.	1.2	16

#	ARTICLE	IF	CITATIONS
217	Anaplastic lymphoma kinase aberrations correlate with metastatic features in pediatric rhabdomyosarcoma. <i>Oncotarget</i> , 2016, 7, 58903-58914.	1.8	15
218	Adamantinoma-like Ewing Family Tumors of the Head and Neck. <i>American Journal of Surgical Pathology</i> , 2015, 39, 1267-1274.	3.7	133
219	A genetic dichotomy between pure sclerosing epithelioid fibrosarcoma (SEF) and hybrid SEF/low-grade fibromyxoid sarcoma: A pathologic and molecular study of 18 cases. <i>Genes Chromosomes and Cancer</i> , 2015, 54, 28-38.	2.8	95
220	Dichotomy of Genetic Abnormalities in PEComas With Therapeutic Implications. <i>American Journal of Surgical Pathology</i> , 2015, 39, 813-825.	3.7	177
221	<i>EWSR1-PBX3</i> : A novel gene fusion in myoepithelial tumors. <i>Genes Chromosomes and Cancer</i> , 2015, 54, 63-71.	2.8	86
222	Molecular Characterization of Inflammatory Myofibroblastic Tumors With Frequent ALK and ROS1 Gene Fusions and Rare Novel RET Rearrangement. <i>American Journal of Surgical Pathology</i> , 2015, 39, 957-967.	3.7	281
223	Frequent FOS Gene Rearrangements in Epithelioid Hemangioma. <i>American Journal of Surgical Pathology</i> , 2015, 39, 1313-1321.	3.7	156
224	<i>CCR</i> 20th Anniversary Commentary: A Genetic Mechanism of Imatinib Resistance in Gastrointestinal Stromal Tumor—Where Are We a Decade Later?. <i>Clinical Cancer Research</i> , 2015, 21, 3363-3365.	7.0	17
225	Combined Inhibition of MAP Kinase and KIT Signaling Synergistically Destabilizes ETV1 and Suppresses GIST Tumor Growth. <i>Cancer Discovery</i> , 2015, 5, 304-315.	9.4	102
226	Novel <i>FUS-KLF17</i> and <i>EWSR1-KLF17</i> fusions in myoepithelial tumors. <i>Genes Chromosomes and Cancer</i> , 2015, 54, 267-275.	2.8	82
227	Pharmacological Inhibition of KIT Activates MET Signaling in Gastrointestinal Stromal Tumors. <i>Cancer Research</i> , 2015, 75, 2061-2070.	0.9	46
228	Tenosynovial giant cell tumour/pigmented villonodular synovitis: Outcome of 294 patients before the era of kinase inhibitors. <i>European Journal of Cancer</i> , 2015, 51, 210-217.	2.8	97
229	Array CGH analysis identifies two distinct subgroups of primary angiosarcoma of bone. <i>Genes Chromosomes and Cancer</i> , 2015, 54, 72-81.	2.8	27
230	Consistent PLAG1 and HMGA2 abnormalities distinguish carcinoma ex-pleomorphic adenoma from its de novo counterparts. <i>Human Pathology</i> , 2015, 46, 26-33.	2.0	103
231	A phase Ib/II study of MEK162 (binimetinib [BINI]) in combination with imatinib in patients with advanced gastrointestinal stromal tumor (GIST). <i>Journal of Clinical Oncology</i> , 2015, 33, 10507-10507.	1.6	16
232	<i>ZFP36-FOSB</i> fusion defines a subset of epithelioid hemangioma with atypical features. <i>Genes Chromosomes and Cancer</i> , 2014, 53, 951-959.	2.8	136
233	Distinct transcriptional signature and immunoprofile of <i>CIC-DUX4</i> fusion—“positive round cell tumors compared to <i>EWSR1</i> —rearranged ewing sarcomas: Further evidence toward distinct pathologic entities. <i>Genes Chromosomes and Cancer</i> , 2014, 53, 622-633.	2.8	201
234	Round cell sarcomas beyond wing: emerging entities. <i>Histopathology</i> , 2014, 64, 26-37.	2.9	168



#	ARTICLE	IF	CITATIONS
235	Novel <i>PRKD</i> gene rearrangements and variant fusions in cribriform adenocarcinoma of salivary gland origin. <i>Genes Chromosomes and Cancer</i> , 2014, 53, 845-856.	2.8	128
236	Recurrent <i>MYOD1</i> mutations in pediatric and adult sclerosing and spindle cell rhabdomyosarcomas: Evidence for a common pathogenesis. <i>Genes Chromosomes and Cancer</i> , 2014, 53, 779-787.	2.8	133
237	Increased KIT Inhibition Enhances Therapeutic Efficacy in Gastrointestinal Stromal Tumor. <i>Clinical Cancer Research</i> , 2014, 20, 2350-2362.	7.0	44
238	<i>EWSR1</i> and <i>ATF1</i> rearrangements in clear cell odontogenic carcinoma: presentation of a case. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2014, 118, e115-e118.	0.4	33
239	Malignant vascular tumors—an update. <i>Modern Pathology</i> , 2014, 27, S30-S38.	5.5	172
240	Novel <i>ZC3H7B</i> – <i>BCOR</i> , <i>MEAF6</i> – <i>PHF1</i> , and <i>EPC1</i> – <i>PHF1</i> fusions in ossifying fibromyxoid tumors—molecular characterization shows genetic overlap with endometrial stromal sarcoma. <i>Genes Chromosomes and Cancer</i> , 2014, 53, 183-193.	2.8	145
241	<i>PRC2</i> is recurrently inactivated through <i>EED</i> or <i>SUZ12</i> loss in malignant peripheral nerve sheath tumors. <i>Nature Genetics</i> , 2014, 46, 1227-1232.	21.4	472
242	Promiscuous genes involved in recurrent chromosomal translocations in soft tissue tumours. <i>Pathology</i> , 2014, 46, 105-112.	0.6	40
243	Consistent <i>SMARCB1</i> homozygous deletions in epithelioid sarcoma and in a subset of myoepithelial carcinomas can be reliably detected by FISH in archival material. <i>Genes Chromosomes and Cancer</i> , 2014, 53, 475-486.	2.8	120
244	<i>NSD3</i> – <i>NUT</i> Fusion Oncoprotein in <i>NUT</i> Midline Carcinoma: Implications for a Novel Oncogenic Mechanism. <i>Cancer Discovery</i> , 2014, 4, 928-941.	9.4	192
245	Dystrophin is a tumor suppressor in human cancers with myogenic programs. <i>Nature Genetics</i> , 2014, 46, 601-606.	21.4	142
246	<i>USP6</i> gene rearrangements occur preferentially in giant cell reparative granulomas of the hands and feet but not in gnathic location. <i>Human Pathology</i> , 2014, 45, 1147-1152.	2.0	92
247	Pathologic and Molecular Features Correlate With Long-Term Outcome After Adjuvant Therapy of Resected Primary GI Stromal Tumor: The ACOSOG Z9001 Trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 1563-1570.	1.6	252
248	Extraskeletal myxoid chondrosarcoma with non- <i>EWSR1</i> - <i>NR4A3</i> variant fusions correlate with rhabdoid phenotype and high-grade morphology. <i>Human Pathology</i> , 2014, 45, 1084-1091.	2.0	83
249	Phase II study of axitinib in patients with progressive, recurrent/metastatic adenoid cystic carcinoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 6093-6093.	1.6	6
250	Alliance A091103: A multicenter phase II study of the angiopoietin-1 and -2 peptibody trebananib (AMG386) for the treatment of angiosarcoma (AS).. <i>Journal of Clinical Oncology</i> , 2014, 32, 10568-10568.	1.6	0
251	Identification of recurrent <i>NAB2</i> - <i>STAT6</i> gene fusions in solitary fibrous tumor by integrative sequencing. <i>Nature Genetics</i> , 2013, 45, 180-185.	21.4	662
252	Novel <i>MIR143</i> – <i>NOTCH</i> fusions in benign and malignant glomus tumors. <i>Genes Chromosomes and Cancer</i> , 2013, 52, 1075-1087.	2.8	138



#	ARTICLE	IF	CITATIONS
253	Novel <i>YAP1</i> – <i>TEF3</i> fusion defines a distinct subset of epithelioid hemangioendothelioma. <i>Genes Chromosomes and Cancer</i> , 2013, 52, 775-784.	2.8	463
254	Recurrent <i>NCOA2</i> gene rearrangements in congenital/infantile spindle cell rhabdomyosarcoma. <i>Genes Chromosomes and Cancer</i> , 2013, 52, 538-550.	2.8	189
255	Frequent <i>PLAG1</i> gene rearrangements in skin and soft tissue myoepithelioma with ductal differentiation. <i>Genes Chromosomes and Cancer</i> , 2013, 52, 675-682.	2.8	104
256	KIT oncogene inhibition drives intratumoral macrophage M2 polarization. <i>Journal of Experimental Medicine</i> , 2013, 210, 2873-2886.	8.5	116
257	Dedifferentiation in Gastrointestinal Stromal Tumor to an Anaplastic KIT-negative Phenotype. <i>American Journal of Surgical Pathology</i> , 2013, 37, 385-392.	3.7	90
258	Clear Cell Odontogenic Carcinomas Show EWSR1 Rearrangements. <i>American Journal of Surgical Pathology</i> , 2013, 37, 1001-1005.	3.7	167
259	Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified liposarcoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, 10512-10512.	1.6	0
260	Alliance A091103: Multicenter phase II study of the angiopoietin-1 and -2 peptibody trebananib for the treatment of angiosarcoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS10592-TPS10592.	1.6	0
261	Imatinib resistance and microcytic erythrocytosis in a Kit <sup>V558F;T669I/+</sup> gatekeeper-mutant mouse model of gastrointestinal stromal tumor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, E2276-83.	7.1	26
262	Monoclonality of multifocal epithelioid hemangioendothelioma of the liver by analysis of WWTR1-CAMTA1 breakpoints. <i>Cancer Genetics</i> , 2012, 205, 12-17.	0.4	86
263	SDHA loss of function mutations in a subset of young adult wild-type gastrointestinal stromal tumors. <i>BMC Cancer</i> , 2012, 12, 408.	2.6	54
264	Epithelioid Hemangioma of Bone and Soft Tissue: A Reappraisal of a Controversial Entity. <i>Clinical Orthopaedics and Related Research</i> , 2012, 470, 1498-1506.	1.5	85
265	Identification of a novel, recurrent <i>HEY1</i> – <i>NCOA2</i> fusion in mesenchymal chondrosarcoma based on a genome-wide screen of exon-level expression data. <i>Genes Chromosomes and Cancer</i> , 2012, 51, 127-139.	2.8	276
266	High prevalence of <i>CIC</i> fusion with double homeobox (DUX4) transcription factors in <i>EWSR1</i> –negative undifferentiated small blue round cell sarcomas. <i>Genes Chromosomes and Cancer</i> , 2012, 51, 207-218.	2.8	307
267	The miR-17-92 cluster and its target <i>THBS1</i> are differentially expressed in angiosarcomas dependent on <i>MYC</i> amplification. <i>Genes Chromosomes and Cancer</i> , 2012, 51, 569-578.	2.8	96
268	Activity of sorafenib in radiation-associated breast angiosarcomas harboring MYC and FLT4 amplifications.. <i>Journal of Clinical Oncology</i> , 2012, 30, 10019-10019.	1.6	5
269	How well do we communicate risk? An evaluation of AJCC version 6 and 7 staging systems for soft tissue sarcomas.. <i>Journal of Clinical Oncology</i> , 2012, 30, 10001-10001.	1.6	0
270	Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. <i>Nature Medicine</i> , 2011, 17, 1094-1100.	30.7	476

#	ARTICLE	IF	CITATIONS
271	Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking <i>KIT</i> and <i>PDGFRA</i> mutations. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 314-318.	7.1	574
272	Advances in sarcoma genomics and new therapeutic targets. Nature Reviews Cancer, 2011, 11, 541-557.	28.4	364
273	The GIST paradigm: lessons for other kinase-driven cancers. Journal of Pathology, 2011, 223, 252-262.	4.5	104
274	Consistent <i>MYC</i> and <i>FLT4</i> gene amplification in radiation-induced angiosarcoma but not in other radiation-associated atypical vascular lesions. Genes Chromosomes and Cancer, 2011, 50, 25-33.	2.8	291
275	<i>EWSR1-ATF1</i> fusion is a novel and consistent finding in hyalinizing clear cell carcinoma of salivary gland. Genes Chromosomes and Cancer, 2011, 50, 559-570.	2.8	339
276	A novel <i>WWTR1-CAMTA1</i> gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites. Genes Chromosomes and Cancer, 2011, 50, 644-653.	2.8	445
277	Consistent t(1;10) with rearrangements of <i>TGFBR3</i> and <i>MGEA5</i> in both myxoinflammatory fibroblastic sarcoma and hemosiderotic fibrolipomatous tumor. Genes Chromosomes and Cancer, 2011, 50, 757-764.	2.8	137
278	<i>EWSR1-POU5F1</i> fusion in soft tissue myoepithelial tumors. A molecular analysis of sixty-six cases, including soft tissue, bone, and visceral lesions, showing common involvement of the <i>EWSR1</i> gene. Genes Chromosomes and Cancer, 2010, 49, 1114-1124.	2.8	443
279	IGF2 overexpression in solitary fibrous tumours is independent of anatomical location and is related to loss of imprinting. Journal of Pathology, 2010, 221, 300-307.	4.5	78
280	ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours. Nature, 2010, 467, 849-853.	27.8	279
281	Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nature Genetics, 2010, 42, 715-721.	21.4	642
282	Crizotinib in <i>ALK</i> -Rearranged Inflammatory Myofibroblastic Tumor. New England Journal of Medicine, 2010, 363, 1727-1733.	27.0	769
283	Clinical Activity of mTOR Inhibition With Sirolimus in Malignant Perivascular Epithelioid Cell Tumors: Targeting the Pathogenic Activation of mTORC1 in Tumors. Journal of Clinical Oncology, 2010, 28, 835-840.	1.6	362
284	<i>KDR</i> Activating Mutations in Human Angiosarcomas Are Sensitive to Specific Kinase Inhibitors. Cancer Research, 2009, 69, 7175-7179.	0.9	247
285	Mechanisms of Sunitinib Resistance in Gastrointestinal Stromal Tumors Harboring <i>KIT</i> AY502-3ins Mutation: An <i>In vitro</i> Mutagenesis Screen for Drug Resistance. Clinical Cancer Research, 2009, 15, 6862-6870.	7.0	86
286	Novel V600E BRAF mutations in imatinib-naïve and imatinib-resistant gastrointestinal stromal tumors. Genes Chromosomes and Cancer, 2008, 47, 853-859.	2.8	329
287	Targeted therapy of cancer: new roles for pathologists in identifying GISTs and other sarcomas. Modern Pathology, 2008, 21, S31-S36.	5.5	48
288	Targeted therapies in gastrointestinal stromal tumors. Seminars in Diagnostic Pathology, 2008, 25, 295-303.	1.5	28

#	ARTICLE	IF	CITATIONS
289	Molecular Profiling in the Diagnosis and Treatment of High Grade Sarcomas. Ultrastructural Pathology, 2008, 32, 37-42.	0.9	14
290	Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor. Journal of Clinical Oncology, 2008, 26, 5352-5359.	1.6	693
291	Molecular Characterization of Pediatric Gastrointestinal Stromal Tumors. Clinical Cancer Research, 2008, 14, 3204-3215.	7.0	233
292	DNA Copy Number Analysis in Gastrointestinal Stromal Tumors Using Gene Expression Microarrays. Cancer Informatics, 2008, 6, CIN.S387.	1.9	3
293	Pathologic and Molecular Heterogeneity in Imatinib-Stable or Imatinib-Responsive Gastrointestinal Stromal Tumors. Clinical Cancer Research, 2007, 13, 170-181.	7.0	118
294	TLE1 as a Diagnostic Immunohistochemical Marker for Synovial Sarcoma Emerging From Gene Expression Profiling Studies. American Journal of Surgical Pathology, 2007, 31, 240-246.	3.7	313
295	L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. International Journal of Cancer, 2007, 121, 257-264.	5.1	236
296	EWSR1-CREB1 is the predominant gene fusion in angiomatoid fibrous histiocytoma. Genes Chromosomes and Cancer, 2007, 46, 1051-1060.	2.8	276
297	Gastrointestinal stromal tumor (GIST) pathogenesis, familial GIST, and animal models. Seminars in Diagnostic Pathology, 2006, 23, 63-69.	1.5	38
298	EWS-CREB1: A Recurrent Variant Fusion in Clear Cell Sarcoma Association with Gastrointestinal Location and Absence of Melanocytic Differentiation. Clinical Cancer Research, 2006, 12, 5356-5362.	7.0	305
299	Deep-Seated Plexiform Schwannoma. American Journal of Surgical Pathology, 2005, 29, 1042-1048.	3.7	83
300	Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation. Clinical Cancer Research, 2005, 11, 4182-4190.	7.0	768
301	Deep-seated plexiform schwannoma: a pathologic study of 16 cases and comparative analysis with the superficial variety. American Journal of Surgical Pathology, 2005, 29, 1042-8.	3.7	54
302	Spectrum of Low-Grade Fibrosarcomas: A Comparative Ultrastructural Analysis of Low-Grade Myxofibrosarcoma and Fibromyxoid Sarcoma. Ultrastructural Pathology, 2004, 28, 321-332.	0.9	45
303	Midline Carcinoma of Children and Young Adults With NUT Rearrangement. Journal of Clinical Oncology, 2004, 22, 4135-4139.	1.6	364
304	Gene Expression in Gastrointestinal Stromal Tumors Is Distinguished by KIT Genotype and Anatomic Site. Clinical Cancer Research, 2004, 10, 3282-3290.	7.0	194
305	Genomic Alterations in Gastrointestinal Stromal Tumors as Revealed by Conventional and Array-based Comparative Genomic Hybridization. Cancer Genomics and Proteomics, 2004, 1, 105-116.	2.0	0
306	Gastrointestinal stromal tumors in a mouse model by targeted mutation of the Kit receptor tyrosine kinase. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 6706-6711.	7.1	220

#	ARTICLE	IF	CITATIONS
307	Congenital and Childhood Plexiform (Multinodular) Cellular Schwannoma. American Journal of Surgical Pathology, 2003, 27, 1321-1329.	3.7	75
308	Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clinical Cancer Research, 2003, 9, 3329-37.	7.0	280
309	PRCC-TFE3 Renal Carcinomas. American Journal of Surgical Pathology, 2002, 26, 1553-1566.	3.7	306
310	MAGE antigen expression in monophasic and biphasic synovial sarcoma. Human Pathology, 2002, 33, 225-229.	2.0	22
311	Molecular Diagnosis of Clear Cell Sarcoma. Journal of Molecular Diagnostics, 2002, 4, 44-52.	2.8	180
312	Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. International Journal of Cancer, 2002, 100, 623-626.	5.1	262
313	Clinicopathologic correlates of solitary fibrous tumors. Cancer, 2002, 94, 1057-1068.	4.1	631
314	Clinicopathologic correlates of solitary fibrous tumors. Cancer, 2002, 94, 1057-1068.	4.1	22
315	Primary Renal Neoplasms with the ASPL-TFE3 Gene Fusion of Alveolar Soft Part Sarcoma. American Journal of Pathology, 2001, 159, 179-192.	3.8	601
316	Sclerosing Epithelioid Fibrosarcoma. American Journal of Surgical Pathology, 2001, 25, 699-709.	3.7	196
317	Clinicopathologic analysis of patients with adult rhabdomyosarcoma. Cancer, 2001, 91, 794-803.	4.1	189
318	Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen ny-eso-1 but not mage-a1 or ct7. International Journal of Cancer, 2001, 94, 252-256.	5.1	182
319	Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nature Medicine, 2001, 7, 673-679.	30.7	2,352
320	The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25. Oncogene, 2001, 20, 48-57.	5.9	562
321	Prognostic impact of P53 status in Ewing sarcoma. Cancer, 2000, 89, 783-792.	4.1	138
322	Prognostic impact of INK4A deletion in Ewing sarcoma. Cancer, 2000, 89, 793-799.	4.1	98
323	Dermatofibrosarcoma Protuberans of the Head and Neck. Annals of Surgical Oncology, 2000, 7, 696-704.	1.5	108
324	Primary Fibrosarcoma and Malignant Fibrous Histiocytoma of Bone - A Comparative Ultrastructural Study: Evidence of a Spectrum of Fibroblastic Differentiation. Ultrastructural Pathology, 2000, 24, 83-91.	0.9	34

#	ARTICLE	IF	CITATIONS
325	Multifocal Angiosarcoma of the Scalp: A Case Report and Review of the Literature. Ear, Nose and Throat Journal, 1999, 78, 302-305.	0.8	16
326	Skeletal and extraskeletal myxoid chondrosarcoma. Cancer, 1998, 83, 1504-1521.	4.1	194